Johnson & Johnson JNJ
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Johnson & Johnson (NYSE: JNJ) is a diversified healthcare company operating across the pharmaceutical and medical technology industries. The company develops, manufactures, and markets products focused on immunology, oncology, neuroscience, cardiovascular disease, surgery, orthopedics, and vision care. Following the separation of its consumer health business into Kenvue in 2023, Johnson & Johnson’s primary revenue drivers are now its Innovative Medicine and MedTech segments. The company serves hospitals, healthcare systems, physicians, distributors, governments, and patients globally, with significant exposure to both developed and emerging healthcare markets.
Johnson & Johnson traces its origins to 1886, when it was founded by Robert Wood Johnson, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey. Historically known for consumer healthcare products alongside pharmaceuticals and medical devices, the company evolved into a more focused healthcare enterprise through decades of acquisitions, research investment, and global expansion. Its strategic positioning is supported by extensive research and development capabilities, strong global distribution networks, a diversified product portfolio, and large-scale manufacturing operations. Information regarding the company’s evolution, segment structure, and strategic transition following the Kenvue separation is consistently reflected in SEC filings, annual reports, and major financial publications.
Business Operations
Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on prescription therapies across oncology, immunology, neuroscience, pulmonary hypertension, and cardiovascular and metabolic diseases. Major products include Darzalex, Stelara, Tremfya, Erleada, and Spravato. The MedTech segment includes surgical technologies, orthopedics, electrophysiology, cardiovascular solutions, contact lenses, and vision-related products through business units such as DePuy Synthes, Ethicon, Biosense Webster, and Johnson & Johnson Vision. Revenue is generated primarily through direct product sales to healthcare providers, wholesalers, and institutional customers.
The company maintains manufacturing, research, and commercial operations across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Johnson & Johnson controls a broad portfolio of intellectual property, production facilities, and medical technology platforms. Strategic collaborations and acquisitions have played a significant role in expanding capabilities, including partnerships in oncology, robotic surgery, and cardiovascular technologies. The company has also maintained significant investments in digital surgery and data-enabled healthcare platforms. Public disclosures in Form 10-K filings and investor presentations consistently identify research and development as a core operational priority.
Strategic Position & Investments
Johnson & Johnson’s strategic direction is centered on high-growth therapeutic areas, advanced medical technologies, and portfolio optimization. Following the separation of Kenvue, the company intensified its focus on pharmaceutical innovation and medical technology expansion. Growth initiatives include next-generation oncology therapies, cell and gene therapy research, robotic-assisted surgery platforms, and cardiovascular intervention technologies. The company continues to invest heavily in research and development, with annual R&D expenditures among the highest in the healthcare industry according to publicly available financial disclosures.
Recent strategic investments and acquisitions include the acquisition of Abiomed, which strengthened Johnson & Johnson’s cardiovascular medical technology portfolio through heart recovery devices and circulatory support systems. The company has also expanded investments in robotic surgery through the Ottava surgical robotics platform and continued development of electrophysiology technologies within Biosense Webster. Johnson & Johnson has historically maintained venture investment activity through innovation-focused initiatives and collaborations with biotechnology firms, universities, and healthcare technology companies. Publicly available filings and investor materials consistently identify oncology, immunology, cardiovascular disease, and digital surgery as long-term strategic priorities.
Geographic Footprint
Johnson & Johnson is headquartered in New Brunswick, New Jersey, United States, and operates in more than 150 countries and territories. The company maintains a substantial commercial and manufacturing presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. The United States remains its largest individual market, although international operations contribute a significant portion of total revenue according to annual financial reporting.
The company’s global footprint includes research centers, production facilities, distribution networks, and regional headquarters across major healthcare markets. Johnson & Johnson has established operational influence in countries including China, Japan, Germany, Switzerland, Ireland, Brazil, and India. Its diversified international presence supports supply chain resilience, regulatory engagement, and localized commercialization strategies. Public company filings and global market analyses consistently confirm the company’s position as one of the world’s largest healthcare enterprises by revenue and market capitalization.
Leadership & Governance
Johnson & Johnson’s leadership structure emphasizes long-term healthcare innovation, operational diversification, and global market expansion. The company’s governance framework is guided by its longstanding corporate philosophy known as the “Credo,” which emphasizes responsibilities to patients, healthcare professionals, employees, communities, and shareholders. Strategic leadership has increasingly focused on pharmaceutical innovation, medtech growth, and operational streamlining following the consumer health separation.
Key executives identified in recent public filings and investor disclosures include:
- Joaquin Duato – Chairman and Chief Executive Officer
- Joseph J. Wolk – Executive Vice President and Chief Financial Officer
- Jennifer L. Taubert – Executive Vice President, Worldwide Chairman, Innovative Medicine
- Tim Schmid – Executive Vice President, Worldwide Chairman, MedTech
- John Reed, M.D., Ph.D. – Executive Vice President, Innovative Medicine Research & Development
- Kathryn E. Wengel – Executive Vice President and Chief Technical Operations & Risk Officer
- Jessica Moore – Executive Vice President, General Counsel
The company was founded by Robert Wood Johnson and his brothers, whose early focus on standardized medical products contributed to the company’s initial growth. Current leadership strategy, as reflected in annual reports and executive communications, prioritizes innovation-driven growth, disciplined capital allocation, and expansion in high-demand therapeutic and medical technology markets.